Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T12:50:54.090Z.
Calculation as of: 2026-10-06T12:50:54.090Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cf0630fc9642b75147419b140bafddb7ccff0a2362c2d95f2dd7172ee2000ae5
PE RATIO
N/A
Market Cap
$903.13M
PE Ratio
N/A
TTM Avg
43.56
3Y Avg
43.56
5Y Avg
43.56
Market Cap
$867.60M
PE Ratio
N/A
TTM Avg
76.88
3Y Avg
76.88
5Y Avg
76.88
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CeriBell, Inc. (CBLL) | $943.26M | N/A | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $922.50M | 5.98 | 5.80 | 5.80 | 5.80 |
| HealthStream, Inc. (HSTM)vs › | $921.45M | 44.09 | 37.03 | 45.62 | 62.08 |
| Bioventus Inc. (BVS)vs › | $915.95M | 17.55 | 40.25 | 40.25 | 34.02 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | N/A | 43.56 | 43.56 | 43.56 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | N/A | 5.99 | 5.99 | 5.99 |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | N/A | 76.88 | 76.88 | 76.88 |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.03B | N/A | 50.11 | 34.45 | 50.26 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$24.86
Forward EPS (Est.)
$-1.97
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
